Last updated: April 26, 2026
What is SILENOR and what is its clinical position?
SILENOR is low-dose doxepin hydrochloride (oral) indicated for sleep maintenance insomnia. The product is differentiated by dose-dependent pharmacology (low-dose regimen primarily targets histamine H1–mediated wakefulness), which supports its clinical use profile in insomnia with sleep-maintenance goals.
Key clinical use profile
- Target condition: Sleep maintenance insomnia
- Therapeutic goal: Increase time asleep / reduce awakenings during the night
- Dosing concept: Low-dose doxepin regimen rather than antidepressant-dose doxepin
Source anchors: FDA labeling for SILENOR describes the approved indication and clinical use. Clinical trial evidence referenced in the labeling supports efficacy in sleep maintenance endpoints. [1]
What do the latest clinical trial records show?
No new, late-stage (Phase 3) efficacy-defining trial data with a clearly attributable “SILENOR” label-expansion outcome is available from the provided record set. The clinically actionable picture remains anchored to the pivotal efficacy program already reflected in FDA labeling.
Current evidence basis (FDA label-backed)
- The approved indication and dosing are supported by randomized clinical trials summarized in the FDA prescribing information for SILENOR. [1]
- Trial endpoints in these studies focus on sleep maintenance outcomes relevant to insomnia, such as wake time after sleep onset (WASO) and sleep efficiency measures (as described in the label). [1]
Where is SILENOR in the competitive landscape for insomnia?
SILENOR competes in sleep maintenance and insomnia treatment more broadly against:
- Non-benzodiazepine hypnotics (Z-drugs)
- Melatonin receptor agonists
- Orexin receptor antagonists
- Benzodiazepines in select use cases
- Other low-dose sedating agents for sleep continuity targets (varies by country)
The practical differentiation for SILENOR is the sleep-maintenance insomnia positioning supported by label-specific claims and clinical trial design reflected in FDA documentation. [1]
How large is the insomnia market that SILENOR addresses?
A precise, drug-specific market size for SILENOR is not present in the available record set, but the market framework is standard:
- Insomnia drug spend is driven by the size of the diagnosed population, prescribing frequency, payer coverage, and duration-of-use patterns.
- Sleep maintenance insomnia is a meaningful segment within insomnia treatment because many branded and generic products target sleep-onset or sleep maintenance differently.
Because there is no provided source set with SILENOR sales, prescriptions, or market share, projection must be grounded in labeled indications and broad insomnia-market dynamics rather than by-calibrated revenue curves.
What is the pricing and access context that matters for projections?
The projection inputs that typically govern low-dose doxepin trajectories are:
- Generic erosion risk: SILENOR faces pricing pressure if doxepin formulations and/or equivalents are available in the relevant dosage and strength formats.
- Formulary placement: Health plans often prefer cost-effective options with predictable safety and guideline-concordant use.
- Switching behavior: Sleep maintenance patients sometimes switch within the insomnia class based on coverage changes, tolerability, and clinician preference.
FDA labeling does not provide pricing forecasts. [1] Therefore, any numerical revenue projection would require sales and pricing history not included in the provided record set.
How should R&D and investment teams think about near-term pipeline risk?
From a patent and lifecycle perspective, low-dose doxepin products tend to face:
- Generic competition if formulation and exclusivity windows have expired
- Next-gen improvements (dose refinement, combination therapy, or new delivery systems) if pursued by the originator or competitors
However, this requires specific patent and exclusivity timelines and pending regulatory filings for SILENOR, which are not available in the provided record set.
What is a defensible market projection without sales and patent expiry data?
A defensible projection is limited to qualitative direction and scenario framing tied to the label and competitive forces, not numeric revenue.
Base-case directional view
- Stable clinical demand: Sleep maintenance insomnia remains a persistent condition segment.
- Margin pressure: Low-dose doxepin products can experience price competition if equivalents exist.
- Formulary dependence: Outcome likely tracks managed-care formularies and prior authorization rules rather than only clinical performance.
Upside levers
- Stronger payer positioning for sleep maintenance indications in formularies
- Evidence generation supporting tolerability and adherence (label-consistent patient segments)
Downside levers
- Broad generic entry at the relevant strength(s)
- Substitution toward newer hypnotics with strong formulary preference
Key clinical and regulatory anchor points for the SILENOR profile
FDA label evidence
- SILENOR is an FDA-approved therapy for sleep maintenance insomnia with clinical trial support summarized in the prescribing information. [1]
Safety and use considerations (label-based)
- The label includes safety information and warnings appropriate to doxepin class effects and insomnia pharmacotherapy. [1]
Key Takeaways
- SILENOR is low-dose doxepin for sleep maintenance insomnia, with efficacy and indication anchored in FDA-labeled clinical trials. [1]
- No new late-stage, SILENOR-specific expansion trial results are available in the provided record set; the practical evidence base remains label-driven. [1]
- Market outlook is primarily determined by formulary access and generic pricing pressure, not by new clinical efficacy signals in the current record set.
- Quantitative market size and revenue projections cannot be stated from the provided sources without sales, pricing, or market-share inputs.
FAQs
-
What condition is SILENOR approved to treat?
Sleep maintenance insomnia. [1]
-
Is SILENOR a benzodiazepine or a Z-drug?
No. It is low-dose doxepin (a tricyclic antidepressant at low doses used for insomnia). [1]
-
What clinical endpoints support SILENOR’s approval?
Sleep maintenance endpoints as summarized in the FDA prescribing information (including measures of wakefulness during the night). [1]
-
What is SILENOR’s main competitive threat?
Pricing and access pressure from alternative insomnia therapies and potential generic competition for doxepin formulations consistent with the strength/dose used for sleep maintenance.
-
What determines near-term growth more than anything?
Managed-care coverage, formulary status, and substitutability within insomnia pharmacotherapy classes.
References
[1] U.S. Food and Drug Administration. (n.d.). SILENOR (doxepin hydrochloride) prescribing information / label. FDA. https://www.accessdata.fda.gov/
